inclusion criteria: * age ≥ 50 years * informed consent by the subject or legally authorized representative * laboratory-confirmed sars-cov-2 infection, as determined by pcr or other commercial or public health assay in any specimen, no more than 4 days prior to the study drug administration * peripheral oxygen saturation ≥ 94% on room air and not requiring supplemental oxygen * onset of symptom is no more than 4 days prior to the study drug administration. onset time of symptom is defined as the time when the patient experienced the presence of at least one of the following (but not limited to) sars-cov-2 infection-associated symptom (fda, september 2020): nasal obstruction or congestion, cough, fever \> 37.3 °c, sore throat, body pain or muscle pain, headache, loss of taste or smell, nausea or vomiting, diarrhoea

inclusion criteria: * age ≥ 50 years * informed consent by the subject or legally authorized representative * laboratory-confirmed sars-cov-2 infection, as determined by pcr or other commercial or public health assay in any specimen, no more than 4 days prior to the study drug administration * peripheral oxygen saturation ≥ 94% on room air and not requiring supplemental oxygen * onset of symptom is no more than 4 days prior to the study drug administration. onset time of symptom is defined as the time when the patient experienced the presence of at least one of the following (but not limited to) sars-cov-2 infection-associated symptom (fda, september 2020): nasal obstruction or congestion, cough, fever \> 37.3 °c, sore throat, body pain or muscle pain, headache, loss of taste or smell, nausea or vomiting, diarrhoea

inclusion criteria: age ≥ 50 years informed consent by the subject or legally authorized representative laboratory-confirmed sars-cov-2 infection, as determined by pcr or other commercial or public health assay in any specimen, no more than 4 days prior to the study drug administration peripheral oxygen saturation ≥ 94% on room air and not requiring supplemental oxygen onset of symptom is no more than 4 days prior to the study drug administration. onset time of symptom is defined as the time when the patient experienced the presence of at least one of the following (but not limited to) sars-cov-2 infection-associated symptom (fda, september 2020): nasal obstruction or congestion, cough, fever > 37.3 °c, sore throat, body pain or muscle pain, headache, loss of taste or smell, nausea or vomiting, diarrhoea

inclusion criteria: age ≥ 50 years informed consent by the subject or legally authorized representative laboratory-confirmed sars-cov-2 infection, as determined by pcr or other commercial or public health assay in any specimen, no more than 4 days prior to the study drug administration peripheral oxygen saturation ≥ 94% on room air and not requiring supplemental oxygen onset of symptom is no more than 4 days prior to the study drug administration. onset time of symptom is defined as the time when the patient experienced the presence of at least one of the following (but not limited to) sars-cov-2 infection-associated symptom (fda, september 2020): nasal obstruction or congestion, cough, fever > 37.3 °c, sore throat, body pain or muscle pain, headache, loss of taste or smell, nausea or vomiting, diarrhoea